share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/14 05:26

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings reported Q3 2024 revenue of $6,580, compared to $10,030 in Q3 2023. Net loss narrowed to $1.41 million from $1.93 million year-over-year, primarily due to decreased interest expenses. Operating expenses totaled $1.42 million, slightly down from $1.45 million in the prior year period.The company's cash position strengthened to $1.98 million as of September 30, 2024, up from $1.28 million at year-end 2023. This improvement was driven by $5.18 million in proceeds from stock sales, partially offset by $3.60 million cash used in operations. General and administrative expenses remained stable at $1.35 million compared to $1.38 million in Q3 2023.Looking ahead, Cardio Diagnostics faces challenges including Nasdaq listing compliance requirements, as its stock price fell below $1.00 minimum bid price. The company has until December 2, 2024, to regain compliance, with a possible 180-day extension. Management continues to focus on expanding product adoption across key channels while developing additional clinical tests for cardiovascular diseases.
Cardio Diagnostics Holdings reported Q3 2024 revenue of $6,580, compared to $10,030 in Q3 2023. Net loss narrowed to $1.41 million from $1.93 million year-over-year, primarily due to decreased interest expenses. Operating expenses totaled $1.42 million, slightly down from $1.45 million in the prior year period.The company's cash position strengthened to $1.98 million as of September 30, 2024, up from $1.28 million at year-end 2023. This improvement was driven by $5.18 million in proceeds from stock sales, partially offset by $3.60 million cash used in operations. General and administrative expenses remained stable at $1.35 million compared to $1.38 million in Q3 2023.Looking ahead, Cardio Diagnostics faces challenges including Nasdaq listing compliance requirements, as its stock price fell below $1.00 minimum bid price. The company has until December 2, 2024, to regain compliance, with a possible 180-day extension. Management continues to focus on expanding product adoption across key channels while developing additional clinical tests for cardiovascular diseases.
心臟診斷控股公司報告2024年第三季度營業收入爲6,580美元,較2023年第三季度的10,030美元有所下降。淨虧損從去年的193萬縮減至141萬,主要得益於利息費用的減少。營業費用總計爲142萬,較上一年同期的145萬略有下降。截至2024年9月30日,公司現金持有量增強至198萬,較2023年年末的128萬有所上升。這一改善主要是由於通過股票銷售獲得的518萬,這部分被運營中使用的360萬現金所抵消。一般和行政費用與2023年第三季度的138萬相比保持穩定,爲135萬。展望未來,心臟診斷面臨挑戰,包括納斯達克上市合規要求,因爲其股價已跌至最低買盤價的1.00美元以下。公司有直到2024年12月2日的時間來恢復合規,可能會有180天的延期。管理層繼續專注於擴大產品在主要渠道的採用,同時開發用於心血管疾病的更多臨牀測試。
心臟診斷控股公司報告2024年第三季度營業收入爲6,580美元,較2023年第三季度的10,030美元有所下降。淨虧損從去年的193萬縮減至141萬,主要得益於利息費用的減少。營業費用總計爲142萬,較上一年同期的145萬略有下降。截至2024年9月30日,公司現金持有量增強至198萬,較2023年年末的128萬有所上升。這一改善主要是由於通過股票銷售獲得的518萬,這部分被運營中使用的360萬現金所抵消。一般和行政費用與2023年第三季度的138萬相比保持穩定,爲135萬。展望未來,心臟診斷面臨挑戰,包括納斯達克上市合規要求,因爲其股價已跌至最低買盤價的1.00美元以下。公司有直到2024年12月2日的時間來恢復合規,可能會有180天的延期。管理層繼續專注於擴大產品在主要渠道的採用,同時開發用於心血管疾病的更多臨牀測試。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息